What's Happening?
The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a new payment model designed to lower prescription drug costs under Medicare Part B. This model targets certain drugs administered
in clinical settings, such as those for cancer or autoimmune conditions, by requiring manufacturers to provide rebates if their prices exceed those in economically comparable countries. The GLOBE Model, which will launch on January 1, 2027, and run for five years, is significantly narrower in scope than initially proposed. Exclusions from the model now include orphan-only drugs, biosimilars and their reference biologics once biosimilar competition enters the U.S. market, Inflation Reduction Act drug price negotiation-eligible drugs, plasma-derived products, and certain cell and gene therapies. These expanded exclusions have drastically reduced the projected savings from $11.9 billion in the proposed rule to an estimated $440 million over five years in the final rule. Manufacturers participating in the Generating Cost Reductions for U.S. Medicaid (GENEROUS) Model are also eligible for a waiver from GLOBE participation, meaning only a limited number of drug manufacturers may be impacted.
Why It's Important?
This finalized GLOBE Model represents a significant, albeit scaled-back, effort by the U.S. government to address high prescription drug costs, particularly for drugs covered under Medicare Part B. The reduction in projected savings from the initial proposal to the final rule highlights the complexities and political pressures involved in drug pricing reforms. While the model aims to reduce out-of-pocket costs for Medicare beneficiaries and save money for the Medicare program, its narrowed scope means a smaller impact than originally envisioned. The exclusions for various drug categories, including biosimilars and certain advanced therapies, indicate a balancing act between cost reduction and fostering innovation or ensuring access to specialized treatments. The model's focus on international benchmarks could set a precedent for future drug pricing policies, influencing how pharmaceutical companies price their products in the U.S. market relative to other developed nations. The limited number of manufacturers expected to be affected also suggests that the immediate, broad-based impact on the pharmaceutical industry may be contained, potentially shifting the burden of cost control to other policy mechanisms or future iterations of such models.
What's Next?
The GLOBE Model is set to commence on January 1, 2027, and will operate for a five-year period. Beneficiaries in randomly selected geographic areas, representing approximately 25% of Medicare beneficiaries enrolled in Original Medicare, could begin to see changes in their out-of-pocket costs as early as April 2027. CMS will continue its manufacturer rebate invoicing and reconciliation activities through March 2034. The implementation of this model will likely be closely monitored by policymakers, pharmaceutical companies, and patient advocacy groups to assess its effectiveness in reducing drug costs and its impact on patient access and pharmaceutical innovation. The limited scope of the current model may lead to future discussions and legislative efforts to expand drug price negotiation or introduce new cost-control mechanisms. The ongoing debate over drug pricing, particularly for Medicare Part B drugs, is expected to continue, with potential for further policy adjustments or new models based on the outcomes and lessons learned from the GLOBE Model's initial years.
Beyond the Headlines
The GLOBE Model's evolution from a broader proposal to a significantly narrowed final rule underscores the persistent tension between drug cost containment and the interests of the pharmaceutical industry. The substantial reduction in projected savings, from $11.9 billion to $440 million, reflects the powerful lobbying efforts and the intricate legal and economic considerations involved in drug pricing. This outcome could be interpreted as a cautious step by CMS, potentially to avoid immediate, widespread disruption to the pharmaceutical market or to mitigate legal challenges from drug manufacturers. The model's reliance on international benchmarks, even with its exclusions, introduces a philosophical shift towards aligning U.S. drug prices with global standards, a concept that has long been debated in American healthcare policy. This could pave the way for more aggressive international reference pricing in the future, depending on the model's success and political will. Furthermore, the exemptions for certain drug categories, such as orphan drugs and cell and gene therapies, highlight the ethical and practical challenges of applying broad pricing controls to highly specialized and often life-saving treatments, where innovation and patient access are paramount concerns.
